About Us
TLI Development History
Robert L. Zeid, Principal Consultant
Mr. Zeid has over 26 years experience in the
pharmaceutical industry having spent the last 20 years in regulatory affairs and product development for
cardiovascular, oncology, anti-ineffective, anti-viral, anti-rheumatic, gastrointestinal,
and biotech products.
Prior to forming TLI
Development in 1997, Mr. Zeid worked in the regulatory affairs groups at AAI
(now aaiPharma), Univax Biologics (now NABI Biologics), and SmithKline & French
Laboratories (now GlaxoSmithKline).
Mr. Zeid also worked as a bench scientist in the
Department of Pharmacology, SmithKline & French Laboratories investigating
post-junctional alpha adrenergic receptor kinetics and dopaminergic agonists as
anti-hypertensive and anti-anginal therapies.
Prior to SmithKline & French Laboratories, he worked
as a bench scientist in the Department of Pharmacology & Toxicology, Wright
State University’s School of Medicine (Dayton, Ohio) investigating the CNS and
cardiovascular effects of a long-lasting methadone derivative on the
dopaminergic receptor population of both the nigro-striatal pathways and
autonomic nervous system (cardiac stellate ganglia).
Mr. Zeid received a Bachelors
of Science degree in
Microbiology from Ohio University in 1979 before continuing post-baccalaureate
studies in neuroanatomy, pharmacology, and law at Wright State University
(Dayton, Ohio.
Over the course of his career,
he also worked as a freelance
medical/technical writer and editor on several projects ranging from novel
anti-infective agents and AIDS products to pharmacology textbooks. He is
currently working on a compendial handbook of stability.
Mr. Zeid is a noted author and speaker on demonstrating
therapeutic equivalence for biotech-derived products. He was a member of the USP
Complex Active Project Team and the Generic Pharmaceuticals Association (GPhA)
Biotechnology Technical Advisory Committee (TAC).
He has also presented on Team
Biologics inspections, electronic tracking systems for change control, and
controlled substances compliances. Details of his
curricula vitae
are provided.
